Product Name: Bcl2 Antibody [ARBC2-1]
Species Reactivity: Human
Tested Applications: Flow, IF, IHC-P, WB
Applications: Flow Cytometry: 0.5-1 ug/million cells in 0.1mlImmunofluorescence: 1-2 ug/mlWestern blot: 1-2 ug/mlImmunohistochemistry (FFPE): 1-2 ug/ml for 30 min at RT (1)Prediluted format: incubate for 30 min at RT (2)Optimal dilution of the Bcl2 antibody should be determined by the researcher.1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 10-20 min followed by cooling at RT for 20 min.2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
User Note: Optimal dilutions for each application to be determined by the researcher
Predicted Molecular Weight:
Immunogen: Recombinant full-length human protein was used as the immunogen for the Bcl2 antibody.
Host Species: Mouse
Purification: Protein G affinity chromatography
Physical State: Liquid
CAS NO.: 3759-92-0
Product: Furaltadone (hydrochloride)
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Conditions: Aliquot and Store at -20C. Avoid freez-thaw cycles.
Clonality: Monoclonal
Conjugate: Unconjugated
Alternate Names: Bcl-2 Antibody: Bcl-2, PPP1R50, Apoptosis regulator Bcl-2
Accession NO.:
Protein Ino:
Official Symbol: BCL2
Geneid: 596
Background: Bcl2 suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release. [UniProt]
PubMed ID:http://aac.asm.org/content/53/12/5275.abstract
